+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Kidney Transplant Rejection - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762874
  • Report
  • April 2019
  • Region: Global
  • 145 pages
  • VPA Research


  • AlphaMab Co Ltd
  • Cinkate Corp
  • Hansa Medical AB
  • JN Biosciences LLC
  • MyeloRx LLC
  • Pharmicell Co Ltd

Kidney Transplant Rejection pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Kidney Transplant Rejection R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Kidney Transplant Rejection report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Kidney Transplant Rejection as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Kidney Transplant Rejection with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Kidney Transplant Rejection pipeline Profiled in detail

Key players actively participating in Kidney Transplant Rejection pipeline are profiled along with their R&D progress in Kidney Transplant Rejection treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Kidney Transplant Rejection pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Kidney Transplant Rejection treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Kidney Transplant Rejection pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Kidney Transplant Rejection pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Kidney Transplant Rejection pipeline study
  • All recent news and developments related to Kidney Transplant Rejection drugs are provided
Note: Product cover images may vary from those shown


  • AlphaMab Co Ltd
  • Cinkate Corp
  • Hansa Medical AB
  • JN Biosciences LLC
  • MyeloRx LLC
  • Pharmicell Co Ltd
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Kidney Transplant Rejection Disease Overview

3. Kidney Transplant Rejection R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Kidney Transplant Rejection Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Kidney Transplant Rejection Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Kidney Transplant Rejection companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Kidney Transplant Rejection Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • AlphaMab Co Ltd
  • Amgen Inc
  • Amyndas Pharmaceuticals LLC
  • Angion Biomedica Corp
  • Astellas Pharma Inc
  • Balmes Transplantation SAS
  • Cinkate Corp
  • F4 Pharma GmbH
  • Genentech Inc
  • Gilead Sciences Inc
  • Hansa Medical AB
  • Helocyte Biosciences Inc
  • Hillhurst Biopharmaceuticals Inc
  • Idogen AB
  • ITB Med AB
  • JN Biosciences LLC
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co Ltd
  • Medeor Therapeutics Inc
  • MyeloRx LLC
  • NextCell Pharma AB
  • Novartis AG
  • Opsona Therapeutics Ltd
  • Pharmicell Co Ltd
  • Pharming Group NV
  • Primatope Therapeutics Inc
  • Prolong Pharmaceuticals LLC
  • Proterris Inc
  • TolerogenixX GmbH
  • TRACT Therapeutics Inc
  • TxCell SA
  • Vitaeris Inc
Note: Product cover images may vary from those shown